TLDR
- OKLO secures first NRC materials license through Atomic Alchemy subsidiary.
- Stock climbs 2.35% as regulatory milestones support nuclear business strategy.
- New license authorizes isotope handling, processing, and distribution capabilities.
- DOE collaboration accelerates Aurora reactor development timeline.
- Company targeting multi-reactor isotope foundry for healthcare and industrial applications.
Shares of Oklo Inc. (OKLO) advanced 2.35% to reach $61.09, rebounding from previous session fluctuations as key regulatory achievements bolstered the company’s expansion strategy. The nuclear technology firm announced significant licensing approval and strengthened its reactor development partnerships. These milestones mark critical progress in the company’s shift from development phase to commercial operations across nuclear energy and isotope sectors.
Atomic Alchemy Subsidiary Receives NRC Materials License
Oklo announced that its Atomic Alchemy subsidiary obtained its inaugural materials license from the U.S. Nuclear Regulatory Commission. This authorization grants permission for managing, processing, and distributing critical radioactive isotopes. The milestone represents the company’s entry into commercial-stage isotope operations.
The regulatory approval encompasses activities related to controlled quantities of radium-226 and sealed calibration sources. It further authorizes chemical processing operations, secure storage, and repackaging under strict regulatory oversight. Consequently, the company can now initiate structured isotope recovery and preparation services.
Operations will be headquartered at the Idaho Radiochemistry Laboratory for initial processing activities. The facility will handle distribution to authorized entities in compliance with federal regulations. This framework creates a regulated channel for domestic isotope supply chain development.
Domestic Isotope Production Capabilities Expand
Oklo intends to transform unused radioactive materials into productive feedstock for medical isotope manufacturing. This initiative addresses critical supply shortages affecting healthcare providers and research institutions. The strategy also diminishes dependence on international isotope imports.
Recovered materials will enable applications ranging from targeted alpha therapy treatments to industrial quality testing. The recycling process maximizes resource utilization by repurposing materials previously designated as waste products. This methodology supports comprehensive nuclear sustainability objectives.
Insights gained from Idaho laboratory operations will guide future large-scale production facilities. The company envisions a multi-reactor isotope foundry featuring multiple small modular reactors. These integrated systems will serve varied applications across medical treatment, defense systems, and space exploration technologies.
Aurora Reactor Project Progresses Through DOE Partnership
The company formalized an agreement with the U.S. Department of Energy to advance its inaugural reactor initiative. This partnership encompasses design specifications, construction phases, and operational protocols within a federal demonstration program. The collaborative framework expedites deployment schedules for next-generation nuclear systems.
The Department of Energy granted approval for a Nuclear Safety Design Agreement covering the Aurora reactor at Idaho National Laboratory. This clearance launches subsequent phases of technical evaluation and project implementation. It simultaneously enables comprehensive safety assessments under federal supervision.
Oklo maintains concurrent development of its fuel fabrication facility located in Idaho. The manufacturing site will produce initial fuel assemblies required for Aurora reactor operations. Collectively, these initiatives reinforce domestic nuclear infrastructure and advance long-term commercial licensing objectives.




